CRISPR Therapeutics' Zugo-cel (CTX112): Next-Gen CAR-T Advances in Phase 1/2

Last updated July 24, 2026: This article originally described a “September 12 PDUFA date” and “October 10 AdCom” for CTX112. These dates appear to be incorrect — no BLA has been filed for CTX112 (now renamed zugocabtagene geleucel, or zugo-cel). The program remains in Phase 1/2 trials in both hematologic malignancies and autoimmune diseases. The article has been rewritten to reflect the actual development status.

CRISPR Therapeutics’ zugocabtagene geleucel (zugo-cel; formerly CTX112) is the company’s next-generation allogeneic CAR-T cell therapy, in development for both B-cell malignancies and autoimmune diseases. It has not yet reached a PDUFA date — no BLA has been filed.

The drug

Zugo-cel is a next-generation allogeneic CAR-T cell therapy targeting CD19. It uses CRISPR gene editing to knock out three genes (TRAC, B2M, PD-1) that limit CAR-T function, and knocks in a CD19-targeting CAR and a HLA-E shield to protect the cells from immune rejection.

In plain English: it’s a more durable, more potent version of first-gen CAR-T, engineered to last longer in the body and resist the tumor’s attempts to shut it down. The “off-the-shelf” (allogeneic) approach doesn’t require collecting the patient’s own cells.

The data

The Phase 1 trial in 32 patients with relapsed/refractory B-cell malignancies showed:

• Overall response rate (ORR): 69%
• Complete response (CR): 59%
• 6-month durability: 82% of CR patients remained in remission at 6 months

The safety profile was manageable: cytokine release syndrome (CRS) in 22% (all Grade 1-2), no Grade 3+ neurotoxicity. No dose-limiting toxicities.

The FDA granted Fast Track designation based on this data.

Expansion into autoimmune disease

In December 2025, CRISPR Therapeutics announced a broad update on zugo-cel, highlighting expansion into autoimmune diseases. The company is running a Phase 1 basket trial in autoimmune rheumatologic diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis. This mirrors the broader industry trend of using CD19 CAR-T to deplete autoreactive B cells in autoimmune conditions.

CRISPR also established a collaboration with Lilly to evaluate zugo-cel together with pirtobrutinib in aggressive B-cell lymphomas, expanding the program’s development in oncology.

The market

CAR-T cell therapies are a $5 billion market, growing 20%+ per year. Current leaders:

• Gilead (Yescarta): ~$1.5B revenue, CD19 CAR-T for lymphoma
• Novartis (Kymriah): ~$0.5B revenue, CD19 CAR-T for leukemia/lymphoma
• J&J/BMS (Carvykti): ~$1B revenue, BCMA CAR-T for myeloma

Zugo-cel enters the CD19 CAR-T market, competing with Yescarta and Kymriah. The differentiator: enhanced potency from CRISPR editing, potentially better durability, and an “off-the-shelf” (allogeneic) manufacturing approach that doesn’t require collecting the patient’s own cells.

If approved, peak sales estimates range from $500M–$1.5B. CRISPR Therapeutics’ market cap is approximately $2.4 billion (at $47.53 per share on July 24, 2026), driven by Casgevy (sickle cell) and the broader pipeline.

What we’re watching

1. Phase 1/2 advancement: Zugo-cel is still in Phase 1/2. No BLA has been filed. The next milestone is larger trial enrollment and potential advancement to Phase 2/3.
2. Autoimmune data: The Phase 1 basket trial in autoimmune diseases (SLE, SSc, inflammatory myositis) could open a significant new market. Data updates are expected in 2026.
3. Lilly collaboration: The combination with pirtobrutinib in aggressive B-cell lymphomas could expand the oncology opportunity.
4. Manufacturing consistency: The allogeneic platform’s manufacturing consistency will be a key regulatory question when a BLA is eventually filed.

CRISPR Therapeutics is building a multi-product company on the gene-editing platform. Zugo-cel is the second program, but it is earlier in development than originally described. The autoimmune expansion is the most interesting new development.

What It Means for the Trade

The correction at the top of this article matters for positioning: there is no PDUFA, no filed BLA, and therefore no near-term regulatory binary on zugo-cel. That makes CRSP’s near-term tradeable value what it has always been — Casgevy’s slow commercial ramp, the exa-cel franchise economics with Vertex, and the pipeline’s long-dated optionality — with zugo-cel as the highest-quality of those options rather than a dated catalyst. The Fast Track designation based on Phase 1 data is a real regulatory posture signal (the FDA doesn’t hand it to unimpressive early data), and the 6-month durability figure (82% of complete responders remaining in remission) is the number that matters most for the program’s credibility, because allogeneic CAR-T’s historical weakness has been persistence — off-the-shelf cells getting cleared by the host immune system before they finish the job.

The market math is where the honest read lives. Peak sales estimates of $500 million to $1.5 billion for zugo-cel assume the allogeneic platform clears two hurdles the Phase 1 hasn’t fully demonstrated: manufacturing consistency at commercial scale, and durability beyond six months in a larger population. Neither is proven, and the $2.4 billion market cap is supported today by Casgevy and the exa-cel partnership, not by zugo-cel’s Phase 1 — which means the program is option value in the current price, and the autoimmune basket is the highest-beta part of that option.

Mechanism and Platform Context

The engineering is what separates zugo-cel from the first allogeneic attempts that disappointed the field. The three knockouts — TRAC (prevents graft-versus-host reaction by removing the T-cell receptor), B2M (removes HLA class I and with it a major rejection channel), and PD-1 (removes the tumor’s primary immune-shutoff lever) — address the three failure modes that killed earlier allogeneic programs. The added HLA-E knock-in is the more sophisticated move: it presents a “don’t kill me” signal to natural killer cells, closing the rejection loop that B2M knockout alone opens (NK cells attack cells lacking HLA class I). The Phase 1 numbers — 69% ORR, 59% CR in 32 relapsed/refractory patients, CRS all grade 1-2, no grade 3+ neurotoxicity — show the construct works on potency and short-term tolerability; durability at scale is the open question the larger trials must answer.

The autoimmune expansion is the strategic pivot worth watching. CD19 CAR-T’s oncology market is contested by entrenched autologal products, but autoimmune disease is the wide-open frontier: SLE, systemic sclerosis, and myositis patients have no B-cell-depletion option with this depth, and the allogeneic format’s immediate availability (no apheresis, no bridge-chemotherapy wait) fits autoimmune practice far better than oncology’s urgent-tumor timeline. A credible signal in the autoimmune basket would re-rate the entire program from “third entrant in CD19 oncology” to “platform for B-cell-driven immune disease.”

Risks and What Could Go Wrong

1. Durability fade at longer follow-up: allogeneic persistence beyond six months is the field’s unproven claim, and any decline in remission maintenance as follow-up extends directly impairs both the oncology and autoimmune theses.
2. Manufacturing consistency: the regulatory question the article flagged — every allogeneic program faces lot-to-lot consistency scrutiny, and a BLA is years out.
3. The oncology competition isn’t standing still: autologous Yescarta/Carvykti-class products keep expanding labels, and the combination work with Lilly’s pirtobrutinib is CRSP’s attempt to buy differentiation in aggressive lymphoma.
4. Graft rejection and the HLA-E shield underperform in larger, more immunologically varied populations — early trial patients are selected in ways real-world populations are not.

Position read: no binary, no filing, no near-term data event defined — CRSP here is a platform-option position, and the correct sizing treats zugo-cel as the highest-conviction leg of a long-dated pipeline. The autoimmune basket data in 2026 is the next checkable milestone.